MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
Sunnybrook Health Science Centre
Toronto, CanadáPublications in collaboration with researchers from Sunnybrook Health Science Centre (4)
2022
-
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
Breast Cancer Research and Treatment
2021
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2015
-
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer
Journal of Clinical Oncology, Vol. 33, Núm. 2, pp. 141-148